PL2483309T3 - Przeciwciała swoiście wiążące się do receptora naskórkowego czynnika wzrostu - Google Patents

Przeciwciała swoiście wiążące się do receptora naskórkowego czynnika wzrostu

Info

Publication number
PL2483309T3
PL2483309T3 PL09850100T PL09850100T PL2483309T3 PL 2483309 T3 PL2483309 T3 PL 2483309T3 PL 09850100 T PL09850100 T PL 09850100T PL 09850100 T PL09850100 T PL 09850100T PL 2483309 T3 PL2483309 T3 PL 2483309T3
Authority
PL
Poland
Prior art keywords
growth factor
factor receptor
epidermal growth
specifically binding
antibodies specifically
Prior art date
Application number
PL09850100T
Other languages
English (en)
Inventor
Se-Ho Kim
Ki Hwan Chang
Kwang-Won Hong
Yong-Won Shin
Min-Soo Kim
Hae-Won Lee
Yong Nam Shin
Kyung Hwan Ryoo
Dong Hyuck Seo
Jong-Hwa Won
Min-Kyu Hur
Original Assignee
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation filed Critical Green Cross Corporation
Publication of PL2483309T3 publication Critical patent/PL2483309T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09850100T 2009-09-29 2009-11-02 Przeciwciała swoiście wiążące się do receptora naskórkowego czynnika wzrostu PL2483309T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090092401A KR101108642B1 (ko) 2009-09-29 2009-09-29 표피 성장 인자 수용체에 특이적으로 결합하는 항체

Publications (1)

Publication Number Publication Date
PL2483309T3 true PL2483309T3 (pl) 2017-02-28

Family

ID=43826456

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09850100T PL2483309T3 (pl) 2009-09-29 2009-11-02 Przeciwciała swoiście wiążące się do receptora naskórkowego czynnika wzrostu

Country Status (20)

Country Link
US (1) US8748175B2 (pl)
EP (1) EP2483309B1 (pl)
JP (1) JP5729839B2 (pl)
KR (1) KR101108642B1 (pl)
CN (1) CN102574919B (pl)
BR (1) BR112012007082B1 (pl)
CA (1) CA2774427C (pl)
DK (1) DK2483309T3 (pl)
ES (1) ES2592883T3 (pl)
HR (1) HRP20161459T1 (pl)
HU (1) HUE030733T2 (pl)
LT (1) LT2483309T (pl)
MX (1) MX2012003662A (pl)
MY (1) MY163502A (pl)
PH (1) PH12012500645A1 (pl)
PL (1) PL2483309T3 (pl)
PT (1) PT2483309T (pl)
RU (1) RU2518239C2 (pl)
SI (1) SI2483309T1 (pl)
WO (1) WO2011040668A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317259A (zh) 2012-03-27 2019-10-11 株式会社绿十字 表皮生长因子受体表面抗原的表位及其用途
EP2879712B1 (en) 2012-07-31 2018-04-25 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
KR101591823B1 (ko) 2013-12-27 2016-02-04 재단법인 목암생명공학연구소 증가된 유전자 발현능을 갖는 발현벡터
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
KR101782632B1 (ko) 2016-01-11 2017-09-27 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암 치료용 조성물
WO2017188472A1 (ko) * 2016-04-27 2017-11-02 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암의 전이 억제용 약학 조성물
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
JP7049389B2 (ja) * 2020-05-01 2022-04-06 グリーン・クロス・コーポレイション 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6699473B2 (en) 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
BRPI0210405B8 (pt) * 2001-06-13 2021-05-25 Genmab As anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
KR100523732B1 (ko) 2004-08-27 2005-10-26 주식회사 녹십자홀딩스 Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체의가변영역을 삽입할 수 있는 항체발현 플라스미드
KR100635370B1 (ko) 2005-03-04 2006-10-17 주식회사 녹십자홀딩스 ＳｃＦｖ 형태의 항체 라이브러리를 제작하기 위한 항체 ＳｃＦｖ 발현벡터
KR100680141B1 (ko) 2005-04-20 2007-02-07 주식회사 녹십자 항-ｅｇｆ 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주
KR100624011B1 (ko) 2005-04-20 2006-09-19 주식회사 녹십자 항-파상풍 단일클론항체 및 이를 생산하는 하이브리도마세포주
JP2009526857A (ja) * 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
EP1829895A1 (en) * 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
EP2134854B1 (en) * 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer

Also Published As

Publication number Publication date
WO2011040668A1 (en) 2011-04-07
JP2013505736A (ja) 2013-02-21
LT2483309T (lt) 2016-11-25
US8748175B2 (en) 2014-06-10
KR20110034914A (ko) 2011-04-06
PT2483309T (pt) 2016-09-02
MX2012003662A (es) 2012-05-08
CN102574919B (zh) 2014-12-10
HRP20161459T1 (hr) 2016-12-16
EP2483309A1 (en) 2012-08-08
BR112012007082A2 (pt) 2017-06-27
CN102574919A (zh) 2012-07-11
CA2774427A1 (en) 2011-04-07
SI2483309T1 (sl) 2016-10-28
JP5729839B2 (ja) 2015-06-03
EP2483309B1 (en) 2016-08-17
CA2774427C (en) 2015-03-31
RU2012117753A (ru) 2013-11-10
MY163502A (en) 2017-09-15
BR112012007082B1 (pt) 2022-07-12
US20120231021A1 (en) 2012-09-13
EP2483309A4 (en) 2013-07-17
RU2518239C2 (ru) 2014-06-10
PH12012500645A1 (en) 2012-11-12
ES2592883T3 (es) 2016-12-02
HUE030733T2 (en) 2017-05-29
KR101108642B1 (ko) 2012-02-09
DK2483309T3 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
IL261916A (en) Antibodies to epidermal growth factor receptor 3 (her3)
IL274615A (en) Antibodies against (3EGFR (3HER
HUS1900048I1 (hu) Anti-IL-23 antitestek
SI2483309T1 (sl) Protitelesa, ki se specifično vežejo na receptor epidermalnega rastnega faktorja
ZA201202162B (en) Insulin receptor binding antibodies
LT3023438T (lt) Anti-gitr antikūnai
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
ZA201202329B (en) Antibodies that specifically bind to the epha2 receptor
IL222657A (en) Epidermal Growth Factor Antibody Antibody Preparation (egfr)
ZA201107511B (en) Antibodies specific to cadherin-17
GB0909906D0 (en) Antibodies
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
EP2596022A4 (en) SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
GB0920324D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0908945D0 (en) Antibodies
HK1172912A (en) Antibodies that specifically bind to the epha2 receptor